5-Jun-2026
Globe Newswire (Wed, 29-Apr 8:55 PM ET)
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Globe Newswire (Tue, 28-Apr 8:53 PM ET)
Globe Newswire (Tue, 14-Apr 8:10 PM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Globe Newswire (Fri, 10-Apr 4:09 PM ET)
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Globe Newswire (Wed, 8-Apr 9:07 AM ET)
Globe Newswire (Tue, 7-Apr 11:35 PM ET)
Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Globe Newswire (Mon, 6-Apr 9:03 PM ET)
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Mesoblast to Host R&D Day on April 8, 2026
Globe Newswire (Tue, 17-Mar 7:19 PM ET)
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of June 5, 2026, MESO stock price declined to $13.95 with 257,653 million shares trading.
MESO has a beta of 1.85, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.14 to the broad based SPY ETF.
MESO has a market cap of $1.80 billion. This is considered a Small Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $51 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $34 million and exceeded earnings estimates by $.17.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, IBBQ, BIB.
MESO has underperformed the market in the last year with a price return of +20.2% while the SPY ETF gained +25.6%. MESO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.0% and -8.2%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
MESO support price is $14.62 and resistance is $15.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.